RCRita Calado

Rita Calado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rita Calado has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Increased antibacterial properties of indoline-derived phenolic Mannich bases

    by Tatu Rimpiläinen, Alexandra Nunes, Rita Calado, Ana S. Fernandes, Joana Andrade, Epole Ntungwe, Gabriella Spengler, Nikoletta Szemerédi, João Rodrigues, João Paulo Gomes, et al.


  • Open Access

    Increased Antibacterial Properties of Indoline-Derived Phenolic Mannich Bases

    by Tatu Rimpilainen, Alexandra Nunes, Rita Calado, Ana Fernandes, Joana Andrade, Epole Ngolle, Gabriella Spengler, Nikoletta Szemeredi, João Rodrigues, João Paulo Gomes, et al.

    The search for antibacterial agents for the combat of nosocomial infections is a timely problem, as antibiotic-resistant bacteria continue to thrive. The effect of indoline substituents on the antibacterial properties of aminoalkylphenols was studied, leading to the development of a library of compounds with minimum inhibitory concentrations (MICs) as low as 1.18 µM. Two novel aminoalkylphenols were identified as particularly promising, after MIC and minimum bactericidal concentrations (MBC) determination against a panel of reference strain Gram-positive bacteria, and further confirmed against 40 clinical isolates (Staphylococcus aureus, S. epidermidis, Enterococcus faecalis, E. faecium, and Listeria monocytogenes). The same two aminoalkylphenols displayed low toxicity against two in vivo models (Artemia salina brine shrimp and Saccharomyces cerevisiae). The in vitro cytotoxicity evaluation (on human keratinocytes and human embryonic lung fibroblast cell lines) of the same compounds was also carried out. They demonstrated a particularly toxic effect on the fibroblast cell lines, with IC50 in the 1.7-5.1 mM range, thus narrowing their clinical use. The desired increase in the antibacterial properties of the alkylaminophenols, particularly indoline-derived phenolic Mannich bases, was reached by introducing an additional nitro group in the indolinyl substituent or by the replacement of a methyl by a bioisosteric trifluoromethyl substituent. Notably, the introduction of an additional nitro moiety did not confer added toxicity to the alkylaminophenols.

  • Open Access

    A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies

    by Rita Calado, Joana Duarte, Pedro Borrego, José Maria Marcelino, Inês Bártolo, Francisco Martin, Inês Figueiredo, Silvia Almeida, Luís Graça, Jorge Vítor, et al.

    Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced Vaccinia viruses expressing a truncated version of gp120 (gp120t) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in mice and rabbits. Mice primed with the recombinant Vaccinia viruses and boosted with the homologous gp120t or C2V3C3 polypeptides developed antibodies that bind potently to homologous and heterologous envelope glycoproteins. Notably, a subset of mice immunized with the CRF02_AG-based envelope immunogens developed a cross-reactive neutralizing response against tier 2 HIV-1 Env-pseudoviruses and primary isolates. Rabbits vaccinated with the CRF02_AG-based envelope immunogens also generated potent binding antibodies, and one animal elicited antibodies that neutralized almost all (13 of 16, 81.3%) tier 2 HIV-1 isolates tested. Overall, the results suggest that the novel CRF02_AG-based envelope immunogens and prime-boost immunization strategy elicit the type of immune responses required for a preventive HIV-1 vaccine.


  • Antibody neutralization and its determinants in HIV-1 infected patients from Portugal: implications for vaccine design and efficacy

    by Patricia Gonçalves, Rute Marcelino, Rita Calado, Francisco Martin, Paloma Gonçalves, Nuno Janeiro, Miguel Neno, Claudia Afonso, Robert Badura, Filipa Gramacho, et al.

    Introduction: Characterizing the antibody response, both neutralizing (NAb) and nonneutralizing (nNAb), in HIV-1 infected patients from Portugal may provide useful insights for vaccine design. We make the first detailed characterization of the Nab and nNAb response in Portuguese patients infected with HIV-1 and identify its determinants. Materials and methods: Plasma samples from a total of 403 patients, 372 on ART and 31 drug naïve, were analysed for neutralizing activity against a reference cross-clade Env-pseudotyped tier 2 virus panel (n = 6, subtypes B, C, AC, and CRF07_BC) and one tier one isolate (NL4.3, subtype B) in a single cycle assay in TZM-bl cells. Binding antibody activity to polypeptides comprising the C2V3C3 envelope regions from different HIV-1 clades (CRF02_AG, B, C, G and H) and peptides from a conserved region in gp41 (3S and EC262A4) was evaluated in ELISA assays. Informed consent for blood collection and study participation was obtained from all participants. The study was approved by the Ethical Boards of the Faculty of Medicine, University of Lisbon and Hospital Egas Moniz. Results: Of the 403 plasma samples tested in ELISA assays, 87.7% reacted with at least one polypeptide. The polypeptide from virus CRF02_AG was the most antigenic (61.1%) followed by H (55.1%), B (51.1%), G (50.9%), C (48.9%), 3S (12.9%) and EC262A4 (11.7%). There was a weak but significant positive correlation between the number of peptides recognized and levels of binding antibodies (r = 0.2678, p = 0.0117). Tier 1 (NL4.3) virus was neutralized by most plasma samples [87.9% (188/214) from patients on ART and 77.4% (24/31) from drug naïve patients]. Out of 39 plasma samples tested against the reference tier 2 panel of pseudoviruses, 23 (59.0%) neutralized all viruses (median 83.4% neutralization) and 14 (35.6%) neutralized between 1-5 viruses (median 48.9% neutralization). A positive correlation was observed between neutralizing potency (% of neutralization) and breadth as defined by the number of viruses neutralized (r = 0.7336, p < 0.0001). Potency of neutralization was higher in treated than in untreated patients (79.4% vs 60.2%, p < 0.0001). The virus PCH119 (clade CFR07_BC) was neutralized by most (82%) plasma samples whereas PCE1176 (clade C) was neutralized by only 61.5% of plasma samples. Discussion and conclusions: The remarkably high prevalence of HIV-1 infected individuals from Portugal with cross-clade neutralizing activity is consistent with the long-term antigenic stimulation of this population by highly diverse HIV-1 clades. Binding antibody response against the C2V3C3 envelope region is a good indicator of neutralization potency in HIV-1 infected individuals from Portugal and it may also be a good indicator of vaccine efficacy.

  • Open Access

    Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells

    by Cheila Rocha, Joana Duarte, Pedro Borrego, Rita Calado, José Maria Marcelino, Rita Tendeiro, Emília Valadas, Ana Espada Sousa, Nuno Taveira

    Potent HIV neutralizing antibodies are critical for vaccination and viral reservoir control. High levels of neutralizing antibodies characterize HIV-2 infection, a naturally-occurring model of attenuated HIV disease with low to undectable viremia. We found that HIV-2-specific antibody potency increased in direct association with the loss of both switched and unswitched memory B-cells in untreated HIV-2 infection. Thus, HIV antibody affinity maturation is linked to memory B-cell exhaustion even in reduced viremia settings.


  • Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola

    by Inês Bártolo, Rita Calado, Pedro Borrego, Thomas Leitner, Nuno Taveira

    Angola has an extremely diverse HIV-1 epidemic fueled in part by the frequent interchange of people with the Democratic Republic of Congo (RDC) and Republic of Congo (RC). Characterization of HIV-1 strains circulating in Angola should help to better understand the origin of HIV-1 subtypes and recombinant forms and their transmission dynamics. In this study we characterize the first near full-length HIV-1 genomic sequences from HIV-1 infected individuals from Angola. Samples were obtained in 1993 from three HIV-1 infected patients living in Cabinda, Angola. Near full-length genomic sequences were obtained from virus isolates. Maximum likelihood phylogenetic tree inference and analyses of potential recombination patterns were performed to evaluate the sequence classifications and origins. Phylogenetic and recombination analyses revealed that one virus was a pure subtype J, another mostly subtype J with a small uncertain region, and the final virus was classified as a H/U/CRF02_AG recombinant. Consistent with their epidemiological data, the subtype J sequences were more closely related to each other than to other J sequences previously published. Based on the env gene, taxa from Angola occur throughout the global subtype J phylogeny. HIV-1 subtypes J and H are present in Angola at low levels since at least 1993. Low transmission efficiency and/or high recombination potential may explain their limited epidemic success in Angola and worldwide. The high diversity of rare subtypes in Angola suggests that Angola was part of the early establishment of the HIV-1 pandemic.


  • Open Access

    Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response

    by Cheila Rocha, Rita Calado, Pedro Borrego, José Maria Marcelino, Inês Bártolo, Lino Rosado, Patrícia Cavaco-Silva, Perpétua Gomes, Carlos Família, Alexandre Quintas, et al.

    Background: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and resulting HIV-2 escape during acute infection and their impact in HIV-2 evolution and disease progression remain largely unknown. Our objective was to characterize the Nab response and the molecular and phenotypic evolution of HIV-2 in association with Nab escape in the first years of infection in two children infected at birth.Results: CD4+T cells decreased from about 50% to below 30% in both children in the first five years of infection and the infecting R5 viruses were replaced by X4 viruses within the same period. With antiretroviral therapy, viral load in child 1 decreased to undetectable levels and CD4+T cells recovered to normal levels, which have been sustained at least until the age of 12. In contrast, viral load increased in child 2 and she progressed to AIDS and death at age 9. Beginning in the first year of life, child 1 raised high titers of antibodies that neutralized primary R5 isolates more effectively than X4 isolates, both autologous and heterologous. Child 2 raised a weak X4-specific Nab response that decreased sharply as disease progressed. Rate of evolution, nucleotide and amino acid diversity, and positive selection, were significantly higher in the envelope of child 1 compared to child 2. Rates of R5-to-X4 tropism switch, of V1 and V3 sequence diversification, and of convergence of V3 to a β-hairpin structure were related with rate of escape from the neutralizing antibodies.Conclusion: Our data suggests that the molecular and phenotypic evolution of the human immunodeficiency virus type 2 envelope are related with the dynamics of the neutralizing antibody response providing further support for a model in which Nabs play an important role in HIV-2 pathogenesis.


  • An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity

    by Pedro Borrego, Rita Calado, José M. Marcelino, Patrícia Pereira, Alexandre Quintas, Helena Barroso, Nuno Taveira

    To produce new fusion inhibitor peptides for HIV-1 and HIV-2 based on ancestral envelope sequences. HIV-2/simian immunodeficiency virus (SIV) ancestral transmembrane protein sequences were reconstructed and ancestral peptides were derived from the helical region 2 (HR2). The activity of one ancestral peptide (named P3) was examined against a panel of HIV-1 and HIV-2 primary isolates in TZM-bl cells and peripheral blood mononuclear cells and compared to T-20. Peptide secondary structure was analyzed by circular dichroism. Resistant viruses were selected and resistance mutations were identified by sequencing the env gene. P3 has 34 residues and overlaps the N-terminal pocket-binding region and heptad repeat core of HR2. In contrast to T-20, P3 forms a typical α-helical structure in solution, binds strongly to the transmembrane protein, and potently inhibits both HIV-2 (mean IC50, 63.8 nmol/l) and HIV-1 (11 nmol/l) infection, including T-20-resistant isolates. The N43K mutation in the HR1 region of HIV-1 leads to 120-fold resistance to P3 indicating that the HR1 region in transmembrane glycoprotein is the target of P3. No HIV-2-resistant mutations could be selected by P3 suggesting that the genetic barrier to resistance is higher in HIV-2 than in HIV-1. HIV-1-infected patients presented significantly lower P3-specific antibody reactivity compared to T-20. P3 is an HIV-2/SIV ancestral peptide with low antigenicity, high stability, and potent activity against both HIV-1, including variants resistant to T-20, and HIV-2. Similar evolutionary biology strategies should be explored to enhance the production of antiviral peptide drugs, microbicides, and vaccines.


  • Baseline Susceptibility of Primary HIV-2 to Entry Inhibitors

    by Pedro Borrego, Rita Calado, José M Marcelino, Inês Bártolo, Cheila Rocha, Patrícia Cavaco-Silva, Manuela Doroana, Francisco Antunes, Fernando Maltez, Umbelina Caixas, et al.

    Background: The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown. Methods: The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cell-based assay. The 50% inhibitory concentration (IC 50 ), 90% inhibitory concentration (IC 90 ) and dose–response curve slopes were determined for each drug. Results: ENF and T-1249 were significantly less active on HIV-2 than on HIV-1 (211- and 2-fold, respectively). AMD3100 and TAK-779 inhibited HIV-2 and HIV-1 CXCR4 tropic (X4) and CCR5 tropic (R5) variants with similar IC 50 and IC 90 values. MVC, however, inhibited the replication of R5 HIV-2 variants with significantly higher IC 90 values (42.7 versus 9.7 nM; P+ T-cells. Conclusions: T-1249 is a potent inhibitor of HIV-2 replication indicating that new fusion inhibitors might be useful to treat HIV-2 infection. Coreceptor antagonists TAK-779 and AMD3100 are also potent inhibitors of HIV-2 replication. The reduced sensitivity of R5 variants to MVC, especially in severely immunodeficient patients, indicates that the treatment of HIV-2-infected patients with MVC might require higher dosages than those used in HIV-1 patients, and should be adjusted to the disease stage.


  • Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal

    by Rita Almeida Calado, Maria Raquel Rocha, Ricardo Parreira, João Piedade, Teresa Venenno, Aida Esteves

    Hepatitis C virus (HCV) infects 2–3% of the world population and intravenous drug consumption is the leading cause of transmission in industrialized countries. The unavailability of data on the molecular epidemiology of HCV infection in Portugal prompted the study of HCV subtypes circulating among intravenous drug users residing in the Lisbon metropolitan area and sampled about 10 years apart (1998–2000 and 2008–2009). Partial coding sequences for E1 and/or NS5B were obtained from 124 individuals with HCV viremia, both mono-infected and co-infected with HIV. Phylogenetic analysis showed that, for both time periods, the most prevalent subtypes were 1a and 3a, found, altogether, in 64.9% and 71.6% of the individuals, respectively for the first and the second sampling periods. However, genotype 4 viruses (subtypes 4a and 4d), introduced later, as inferred by comparison of intra-subtype genetic distances, were also relatively frequent even one decade ago (24.6%). This HCV subtype profile for Portuguese intravenous drug users is in agreement with those described for other southern European countries when in association with drug consumption. With the exception of subtype 1b, phylogenetic trees did not show clustering of the Portuguese sequences, but rather phylogenetic mixing of HCV sequences from different geographic origins, as described previously in other Western countries and suggestive of a large international transmission network. Consistent with the low recombination rates reported for HCV, only one sample revealed discordant subtypes for the two regions analyzed (4d in E1 and 4a in NS5B), representing a potential new recombinant that deserves further analysis. J. Med. Virol. 83:608–615, 2011.